Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy as neoadjuvant and adjuvant treatment for resectable locally advanced non-small cell lung cancer
ChiCTR2000031588Phase 2Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University General Hospital. Primary endpoint: 3-year progression-free survival rate. Started May 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000031588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031588.